Clinical Trials Logo

Filter by:
NCT ID: NCT05056064 Recruiting - Oral Cavity Cancer Clinical Trials

Efficacy of Swallowing Function After Early Postoperative Oral Exercise Among Patient With Oral Cavity Cancer Underwent Flap Reconstruction

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Efficacy of swallowing function after early postoperative oral exercise among patient with oral cavity cancer underwent flap reconstruction: A randomized controlled trial

NCT ID: NCT05052502 Recruiting - Clinical trials for Plasmodium Falciparum Malaria

Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand

COMBAT
Start date: November 1, 2020
Phase: N/A
Study type: Interventional

This study assesses the effectiveness of reactive focal mass drug administration (rfMDA), targeting both village and forest working populations, compared to control for reducing the health promotion hospital-level (sub-district) incidence and prevalence of P. falciparum and P. vivax within five provinces in Thailand.

NCT ID: NCT05052242 Completed - Clinical trials for Primary Angle Closure Glaucoma

Evaluation of Ocular Biometry in PACD With Two Swept Source Optical Coherence Tomography Devices

Start date: May 1, 2020
Phase:
Study type: Observational

Purpose: To investigate agreement between 2 swept source OCT biometers, IOL M.aster700 and Anterion, in various ocular biometry and intraocular lens (IOL) calculations of primary angle-closure disease (PACD). Methods: This was a prospective study conducted in a tertiary eye care centre involving biometric measurements obtained with 2 devices in phakic eye with diagnosis of PACD. Mean difference and intraclass correlation coefficient (ICC) with confidence limits were assessed, and calculations of estimated residual refraction of the IOL were analysed using Barrett's formula.

NCT ID: NCT05047835 Recruiting - Clinical trials for Cardiovascular Diseases

Comparison of Prone Position and Standard Electrocardiogram in COVID-19 Patients

Start date: September 10, 2021
Phase:
Study type: Observational

Prolonged prone position ventilation reduces the 30-day mortality in acute respiratory distress syndrome (ARDS) and in COVID-19 infection. A large number of patients with COVID-19 suffered from new-onset cardiac disease, therefore, ECG is crucial. However, there is limited data on the effects of prone position on the ECG in COVID-19 patients.

NCT ID: NCT05043389 Recruiting - Clinical trials for Obstructive Sleep Apnea

Impact of Myofuntional Therapy Program on Increasing Tongue Strength and Improving Sleep Apnea

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This Research studies for compare muscle strength among OSA patients who treat with myofunctional therapy program in Rajavithi hospital

NCT ID: NCT05042271 Recruiting - Autoimmune Diseases Clinical Trials

PK of Meropenem in Patients on Plasma Exchange

Start date: January 1, 2020
Phase:
Study type: Observational

Therapeutic plasma exchange (TPE) has been shown to be an important procedure for treatment of a variety of refractory immune complex disorders, such as Guillain-Barré syndrome and neuromyelitis optica. The intervention removes plasma, albumin, or some other substance. Meropenem is a broad-spectrum beta-lactam antimicrobial agent that is used for the treatment of serious nosocomial infections. Pathophysiological changes in patients on TPE can alter the pharmacokinetic (PK) patterns of coadministered antibiotics. This effect has an impact on the antimicrobial agents when paticipants are administered during the intervention. The aim of this study was to investigate the impact of TPE on meropenem PK.

NCT ID: NCT05041907 Not yet recruiting - COVID-19 Clinical Trials

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

PLATCOV
Start date: September 2021
Phase: Phase 2
Study type: Interventional

The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19. In this randomised open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: potentially effective repurposed antiviral drugs; B: Positive control: we will initially include the REGN-COV2 (monoclonal antibody cocktail); and later: C: any future small molecule drugs that pass phase 1 testing. PLATCOV study is funded by ACT-Accelerator Therapeutics Partnership through the Wellcome Trust. The grant reference number is 223195/Z/21/Z

NCT ID: NCT05037539 Recruiting - Pain, Breakthrough Clinical Trials

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

Start date: June 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized control trial that to comparison the efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain Primary outcome : to measure pain score after drug is given

NCT ID: NCT05036616 Recruiting - AKI Clinical Trials

Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial

Start date: April 1, 2021
Phase:
Study type: Observational

This investigation aims to evaluate the filter life time of CRRT membrane and complication of combining ECMO and CRRT.

NCT ID: NCT05033522 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Immunotherapy for Advanced Liver Cancer

ALIVE
Start date: February 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for naïve Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including subjects with vascular involvement and/or extrahepatic spread (not eligible for TACE, surgery or locoregional treatment) with Child-Pugh stage A or B liver function and either unable to assess, or not eligible for, sorafenib first line treatment. 180 subjects will be randomized 2:1 to AlloStim® immunotherapy vs Physician's Choice of Best Supportive Care or FOLFOX4 chemotherapy.